Kirtland Poss

VisEn's in vivo fluorescence imaging technologies, including its Fluorescence Agent Portfolio and its Fluorescence Molecular Tomographic (FMTTM) Imaging Systems provide robust fluorescence molecular imaging performance in identifying, characterizing and quantifying ranges of disease biomarkers and therapeutic efficacy in vivo. VisEn's FMT systems and agents are used by leading research institutions and pharmaceutical companies in applications including cancer research, inflammation, cardiovascular, skeletal and pulmonary disease. The company also works with large pharmaceutical partners to design ranges of tailored molecular imaging agents and applications that are designed to their specific pre-clinical and clinical research areas.

BioAnalytix, Inc. develops and applies advanced analytic technologies. It offers advanced analytics, biologic therapeutics, mass spec, drug development and biopharma technologies. The company was founded by Barry L. Karger and Kirtland G. Poss in 2012 and is headquartered in Cambridge, MA.

The General Hospital Corp. provides healthcare services. It offers diagnostic and therapeutic are in every specialty and subspecialty of medicine and surgery. The firm's care center provides cancer, digestive disorders, heart disease, transplantation and vascular medicine services. The company was founded in 1811 and is headquartered in Boston, MA.

Edgewater Capital Partners (Edgewater Capital Partners) is a private equity firm founded in 1998 by Christopher F. Childres and Edward L. Sawyer. The firm is headquartered in Cleveland, Ohio.

Molecular Imaging, Inc. provides research services supported by extensive in vivo imaging capabilities. Its services include oncology pharmacology, immuno-oncology, imaging, radiation, and in vivo biodistribution. The company was founded by Wilbur R. Leopold, John Fleming, and Patrick McConville in 2003 and is headquartered in Ann Arbor, MI.

Protagene CGT GmbH engages in the development of research concepts and platforms for DNA and RNA fusion sequences. Its products include Vector safety, AAV Vector quality control, immune repertoire analyses, target analyses in gene editing, as well as bioinformatics and next generation sequencing. The company was founded by Christof von Kalle, Manfred Schmidt, and Annette Deichmann in July 2014 and is headquartered in Heidelberg, Germany.